Medtronic plc (NYSE: MDT), a healthcare technology company, on Tuesday said the US Food and Drug Administration (FDA) has cleared its Hugo robotic-assisted surgery (RAS) system for general surgery procedures.
The clearance covers all upper abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia and small bowel resection. Inguinal hernia and appendectomy, both lower abdominal procedures, were also cleared. Together, these account for about 3.5 million US surgeries a year, more than half of all soft-tissue procedures performed in the country annually.
Medtronic said that, globally, Hugo RAS system procedure growth is running at more than twice the pace of the robotic surgery market. The company expects to surpass 50,000 procedures by the end of its fiscal year. Outside the US, general surgery has become the highest-growth area for the system, ahead of urology and gynaecology.
For US hospitals, the decision widens the system's use beyond urology.
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels